DexCom, Inc. reported past first-quarter 2026 results with revenue of US$1,191.9 million, net income of US$199.5 million, and diluted EPS of US$0.51, while reaffirming full-year revenue guidance of ...

Dexcom () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smarter ...

Dexcom has opted not to raise its FY26 revenue outlook due to the current geopolitical environment.

April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its ...

DexCom (NASDAQ:DXCM) reported first-quarter 2026 revenue growth of 15% year over year, citing continued demand for continuous ...

Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday ...

DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...

SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported first-quarter earnings of $199.5 million. The San Diego-based company said it had profit of 51 cents per share. Earnings, ...

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...

They offer investors very different value propositions.

“This small thing,” Nick Jonas says while holding the all-new Dexcom G7 Continuous Glucose Monitoring (CGM) system in his hand at the start of the new commercial for Super Bowl LVII. With a snap of ...